Treatment Information

Back

Breast Cancer treatment details. Chemotherapy.

Erasmus University Medical Center, Rotterdam, Netherlands.

Survival: monthsCountry:Netherlands
Toxiciy Grade:4City/State/Province:Rotterdam
Treatments:ChemotherapyHospital:Erasmus University Medical Center
Drugs:Journal:Link
Date:Oct 2005

Description:

Patients: This Phase II/III study involved 216 women with metastatic breast cancer who were randomly assigned into two groups. Group A had 109 women (median age 53). Metastatic sites included viscera, bone, lung, and liver, with 47 patients having metastases in three or more organs.

Treatment: For Group A, treatment consisted of two chemotherapeutic agents: doxorubicin and docetaxel.

Toxicity: There were two toxic deaths. In addition, grade 3-4 toxicities include neutropenia (with fever), nausea, infection, neurotoxicity, and stomatitis.

Results: Patients in Group A had a significantly longer overall survival (22.6 months) than patients in Group B (16.2 months). Sixty-three Group A patients had a response to treatment, while forty Group B patients responded.

Support: Aventis Pharmaceuticals financially supported this study, and one of the authors is an employee. Aventis manufactures and markets docetaxel.

Correspondence: Marijke Bontenbal, MD, PhD




Back